Diabetes drug may aid multiple sclerosis
Posted on: Wednesday, 27 May 2009, 15:51 CDT
U.S. medical researchers say they've found a drug used to treat diabetes shows protective effects in the brains of some multiple sclerosis patients.
Researchers at the University of Illinois-Chicago College of Medicine say they conducted a small, double-blind clinical trial involving patients with relapsing remitting multiple sclerosis. The patients were assigned to take pioglitazone -- a type 2 diabetes drug commercially known as Actos -- or a placebo. Patients continued their normal course of therapy during the trial.
The scientists said patients taking pioglitazone showed significantly less loss of gray matter during the course of the one-year trial than patients taking placebo. Of the 21 patients who finished the study, patients taking pioglitazone had no adverse reactions.
This is very encouraging,
said Professor Douglas Feinstein. Gray matter in the brain is the part that is rich in neurons. These preliminary results suggest the drug has important effects on neuronal survival.
The scientists also tested pioglitazone in an animal model of MS and found the drug can significantly reduce the clinical signs in mice with an MS-type disease,
said Feinstein.
More importantly, when mice who are already ill are treated with pioglitazone, the clinical signs of the disease go away,
he said.
The study is reported in the online edition of the Journal of Neuroimmunology.
Source: United Press International
Related Articles
- TRACON Pharmaceuticals Doses the First Patient in a Phase 1 Clinical Trial With Oral TRC102, An Inhibitor of Chemotherapy Resistance, in Combination With Alimta
- NuRx Pharmaceuticals Doses First Patient in Phase I Clinical Trial of First-in-Class RXR Agonist NRX4204
- Treatment of First Patient in Phase I Clinical Trial of Bionomics' Anti-Cancer Drug BNC105
- Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
- Medivation Announces Treatment of First Patient in Phase 1-2 Clinical Trial of MDV3100 in Hormone-Refractory Prostate Cancer
- Boston Scientific Announces First Patient Implanted in Clinical Trial Assessing Neurostimulation As a Treatment for Migraine
- MedImmune Begins Dosing of Lupus Patients in Phase 1 Clinical Trial
- Celgene cancer drug clinical trial suspended - WSJ
- State May Require Details of Drug Clinical Trials
- GelStat Corporation Completes Patient Enrollment in Clinical Trial of GelStat Migraine in Triptan Users
 |
 |
User Comments (0)
RSS Feeds